# Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

> **NCT01723657** · PHASE2 · COMPLETED · sponsor: **Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias** · enrollment: 862 (actual)

## Conditions studied

- Leukemia, Myelocytic, Acute

## Interventions

- **DRUG:** Ara-C
- **OTHER:** Autologous peripheral blood stem cell transplantation.
- **OTHER:** Allogeneic matched related or unrelated donor transplant.
- **DRUG:** G-CSF
- **OTHER:** CD34+ selection.
- **OTHER:** Mylotarg purging before autologous PBSC transplantation

## Key facts

- **NCT ID:** NCT01723657
- **Lead sponsor:** Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 862 (ACTUAL)
- **Last updated:** 2012-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723657, "Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01723657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*